Oxford Brain Diagnostics Ltd Risk Report

📜 Innovation & R&D

Oxford Brain Diagnostics Ltd is at the forefront of innovation in brain health diagnostics, specifically focusing on Alzheimer's and dementia-related conditions. Their work in pioneering new diagnostic technologies has potential to transform early detection and management of neurodegenerative diseases. Recent advancements and collaborations signal a promising trajectory for Oxford Brain Diagnostics in both research and clinical applications.

• On 🗓 May 27, 2025, the company announced the commercialisation of its dementia diagnostic tools, aiming to roll out in both the UK and US markets.
• Oxford Brain Diagnostics initiated a research collaboration with Memory Treatment Centers in Florida to explore Alzheimer's disease metrics in patients undergoing anti-amyloid treatment on 🗓 September 18, 2024.
• As of 🗓 December 23, 2024, the company started a blood test trial across the UK to aid in detecting dementia.
• They've achieved FDA clearance for brain MRI-based software to assess cortical disarray on 🗓 January 16, 2025.
• A revolutionary brain scan technology was reported on 🗓 May 25, 2025, to detect Alzheimer's before symptoms appear.